Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
Stock Information for Corbus Pharmaceuticals Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.